Transcatheter aortic valve implantation in patients with tricuspid, bicuspid and bioprosthetic valves: observations from COMPARE-TAVI 1.
Scand Cardiovasc JSep 21, 2026 (epub)
Clinical ResearchCardiology
Troels Thim, Henrik Nissen, Phillip Freeman et al.
✦ AI-curated · Sources linked
In 30 seconds
This study analyzed outcomes of transcatheter aortic valve implantation (TAVI) in patients with tricuspid, bicuspid, and bioprosthetic valves from the COMPARE-TAVI 1 trial. The randomized controlled trial included 1,030 patients, revealing no significant differences in 30-day or 1-year outcomes across valve types. Notably, no patients with bioprosthetic valves required a new pacemaker within 30 days post-procedure.
Key findings
- No differences in death or bleeding at 30 days among valve types.
- Stroke occurred more frequently in patients with bicuspid valves at 30 days (n = 7).
- No patients with bioprosthetic valves required a new pacemaker within 30 days.
- Reoperation was more frequent among patients with bicuspid valves (n = 3).
Why it matters
Understanding the outcomes of TAVI across different valve anatomies is crucial for clinicians to make informed decisions regarding patient management and procedural expectations, particularly in older populations.